Stanford Starts Par Pharmaceutical (PRX) at Hold
More News related to PRX
- Par Pharmaceutical (PRX) Halts Shipments of of Budesonide Inhalation Suspension
- Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension
- Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
- Matrix Lighthouse Rating Changes 11/14
- Par Pharmaceuticals (PRX) Tops Q3 View
More News related to New Coverage
- Friedman Billings Starts Aircastle (AYR) at Underperform
- Friedman Billings Starts Netflix (NFLX) at Market Perform
- Credit Suisse Starts 3PAR (PAR) at Neutral
- Credit Suisse Starts Netezza (NZ) at Neutral
- FBR Starts Amazon.com (AMZN) at Market Perform
Stanford Group initiates coverage on Par Pharmaceutical Companies (NYSE: PRX) with a Hold rating.
Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States.
Related Categories
New CoverageStocks Mentioned
+0.22Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
